BR112021021600A2 - Método para tratamento de tosse usando composto de diaminopirimidina - Google Patents

Método para tratamento de tosse usando composto de diaminopirimidina

Info

Publication number
BR112021021600A2
BR112021021600A2 BR112021021600A BR112021021600A BR112021021600A2 BR 112021021600 A2 BR112021021600 A2 BR 112021021600A2 BR 112021021600 A BR112021021600 A BR 112021021600A BR 112021021600 A BR112021021600 A BR 112021021600A BR 112021021600 A2 BR112021021600 A2 BR 112021021600A2
Authority
BR
Brazil
Prior art keywords
cough
diaminopyrimidine compound
compound
treating
treating cough
Prior art date
Application number
BR112021021600A
Other languages
English (en)
Portuguese (pt)
Inventor
Hongjun Wang
Huai Huang
Huining Liang
Jin Wang
Liying Zhou
Ran An
Yanan Liu
Yanping Zhao
Yuanyuan Jiang
Zhou Lan
Original Assignee
Beijing Tide Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Tide Pharmaceutical Co Ltd filed Critical Beijing Tide Pharmaceutical Co Ltd
Publication of BR112021021600A2 publication Critical patent/BR112021021600A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112021021600A 2019-04-30 2020-04-29 Método para tratamento de tosse usando composto de diaminopirimidina BR112021021600A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019085180 2019-04-30
PCT/CN2020/087686 WO2020221274A1 (zh) 2019-04-30 2020-04-29 二氨基嘧啶类化合物治疗咳嗽的方法

Publications (1)

Publication Number Publication Date
BR112021021600A2 true BR112021021600A2 (pt) 2022-01-04

Family

ID=73029672

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021021600A BR112021021600A2 (pt) 2019-04-30 2020-04-29 Método para tratamento de tosse usando composto de diaminopirimidina

Country Status (12)

Country Link
US (1) US20220211703A1 (cg-RX-API-DMAC7.html)
EP (1) EP3960179B1 (cg-RX-API-DMAC7.html)
JP (1) JP7665529B2 (cg-RX-API-DMAC7.html)
KR (1) KR102935436B1 (cg-RX-API-DMAC7.html)
CN (1) CN114007619B (cg-RX-API-DMAC7.html)
AU (1) AU2020265327B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021021600A2 (cg-RX-API-DMAC7.html)
ES (1) ES3067370T3 (cg-RX-API-DMAC7.html)
MX (1) MX2021013338A (cg-RX-API-DMAC7.html)
SG (1) SG11202111877TA (cg-RX-API-DMAC7.html)
TW (1) TWI736243B (cg-RX-API-DMAC7.html)
WO (1) WO2020221274A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117186068A (zh) * 2017-11-01 2023-12-08 北京泰德制药股份有限公司 P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1725540E (pt) * 2004-03-05 2012-11-29 Hoffmann La Roche Diaminopirimidinas como antagonistas de p2x3 e p2x2/3
ES2612890T3 (es) * 2005-09-01 2017-05-19 F. Hoffmann-La Roche Ag Diaminopirimidinas como moduladores de P2X3 y P2X2/3
DK2343281T3 (en) 2006-10-04 2014-03-24 Hoffmann La Roche Process for the Synthesis of Phenoxydiamino-Pyrimidine Derivatives
PE20160431A1 (es) * 2013-08-23 2016-06-02 Afferent Pharmaceuticals Inc Moduladores del receptor p2x3 y p2x2/3 de diaminopiridina para el tratamiento de la tos aguda, sub-aguda o cronica
CA2998742C (en) * 2015-09-29 2023-08-29 Anthony P. FORD Diaminopyrimidine p2x3 and p2x2/3 receptor modulators for use in the treatment of cough
US10822311B2 (en) * 2016-03-14 2020-11-03 Afferent Pharmaceuticals, Inc. Pyrimidines and variants thereof, and uses therefor
AU2017237929B2 (en) * 2016-03-25 2021-04-15 Afferent Pharmaceuticals Inc. Pyrimidines and variants thereof, and uses therefor
CN117186068A (zh) * 2017-11-01 2023-12-08 北京泰德制药股份有限公司 P2x3和/或p2x2/3受体拮抗剂、包含其的药物组合物及其用途

Also Published As

Publication number Publication date
ES3067370T3 (en) 2026-05-21
JP7665529B2 (ja) 2025-04-21
JP2022530890A (ja) 2022-07-04
KR102935436B1 (ko) 2026-03-05
SG11202111877TA (en) 2021-11-29
MX2021013338A (es) 2022-01-24
TWI736243B (zh) 2021-08-11
EP3960179A1 (en) 2022-03-02
KR20220007620A (ko) 2022-01-18
US20220211703A1 (en) 2022-07-07
AU2020265327A1 (en) 2021-12-16
CN114007619B (zh) 2024-08-06
EP3960179B1 (en) 2026-03-18
CN114007619A (zh) 2022-02-01
TW202106302A (zh) 2021-02-16
EP3960179A4 (en) 2023-01-25
CA3138780A1 (en) 2020-11-05
AU2020265327B2 (en) 2025-09-11
WO2020221274A1 (zh) 2020-11-05

Similar Documents

Publication Publication Date Title
SA522433155B1 (ar) مركبات ثلاثية الحلقة مستبدلة
MX2024004332A (es) Metodos de uso de inhibidores de ehmt2 para tratar o prevenir transtornos sanguíneos.
EA201891191A1 (ru) 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения
CL2023001369A1 (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
SA518391836B1 (ar) تيتراهيدروبيرانيل أمينو-بيرولوبيريميدينون وطرق استخدامه
BR112013021566A2 (pt) composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula
BR112021017354A2 (pt) Método para o tratamento de doença hepática adiposa e/ou esteatoepatite
MX2013012588A (es) Inhibidores de cinasa.
BR112012026767A2 (pt) composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal
EA201690752A1 (ru) Ингибиторы g12c kras
NZ756231A (en) A novel isoindoline derivative, a pharmaceutical composition and use thereof
EA201491362A1 (ru) Анестезирующие соединения и способы их применения
HK1201065A1 (en) Novel quinoxaline inhibitors of pi3k
PH12022551523A1 (en) Cyclic compounds and methods of using same
MX2010001189A (es) Derivados de naftiridina como modulares del canal de potasio.
EA201690386A1 (ru) Соединения и композиции в качестве ингибиторов mek
BR112013028430A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição mediada por tirosina quinase do baço (syk), e, uso de uma quantidade terapeuticamente eficiente do composto
MY194087A (en) Use of gabaa receptor reinforcing agent in preparation of sedative and anesthetic medicament
BR112021026214A2 (pt) Método para tratamento de fibrose pulmonar idiopática
MX2021009806A (es) Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos.
BR112015020600A2 (pt) composição farmacêutica, método para o tratamento de e/ou melhorar doenças de gordura no fígado de origem não alcoólica e uso da composição
BR112016015235A2 (pt) Composto, composição farmacêutica, método de inibição da atividade da proteína quinase erk e método de tratamento
MY196788A (en) Fused tricyclic ?-amino acid derivative, preparation method therefor, and medical use thereof
MY165902A (en) Substituted pyridine derivatives as fabi inhibitors
PH12018500653B1 (en) Salts and solid forms of monobactam antibiotic

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]